Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSG-ARA Plus: Darbepoetin alfa in Adjuvant Breast Cancer
NCT00309920Phase 3Unknown
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Jan 2004
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa in breast cancer (2 arms), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
darbepoetin alfa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00309920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309920.